Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

C4 Therapeutics (CCCC) Shares Outstanding (2019 - 2026)

C4 Therapeutics has reported Shares Outstanding over the past 8 years, most recently at $104.0 million for Q1 2026.

  • For Q1 2026, Shares Outstanding rose 46.55% year-over-year to $104.0 million; the TTM value through Mar 2026 reached $104.0 million, up 46.55%, while the annual FY2025 figure was $96.9 million, 37.22% up from the prior year.
  • Shares Outstanding for Q1 2026 was $104.0 million at C4 Therapeutics, up from $96.9 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $104.0 million in Q1 2026 and troughed at $48.8 million in Q1 2022.
  • A 5-year average of $64.7 million and a median of $68.8 million in 2024 define the central range for Shares Outstanding.
  • Biggest five-year swings in Shares Outstanding: increased 0.38% in 2023 and later skyrocketed 46.55% in 2026.
  • Year by year, Shares Outstanding stood at $49.0 million in 2022, then grew by 23.49% to $60.5 million in 2023, then grew by 16.8% to $70.6 million in 2024, then surged by 37.22% to $96.9 million in 2025, then increased by 7.35% to $104.0 million in 2026.
  • Business Quant data shows Shares Outstanding for CCCC at $104.0 million in Q1 2026, $96.9 million in Q4 2025, and $74.2 million in Q3 2025.